TLDR
- Artelo Biosciences (ARTL) experienced a pre-market surge exceeding 40% on March 18, 2026
- The rally followed news of a collaboration with Belfast Health and Social Care Trust for a fully-funded glaucoma research trial
- The clinical trial will evaluate ART27.13, the company’s peripherally acting synthetic cannabinoid, in glaucoma and ocular hypertension patients
- Glaucoma UK and HSC R&D Division are providing complete funding, with initial patient dosing anticipated in Q2 2026
- This announcement comes after a 1-for-3 reverse stock consolidation completed March 10, 2026
Shares of Artelo Biosciences (ARTL) skyrocketed over 40% during Wednesday’s pre-market session following the company’s revelation of a completely funded clinical investigation examining its synthetic cannabinoid therapy ART27.13 for glaucoma management.
Artelo Biosciences, Inc., ARTL
The investigator-led clinical trial was established through a partnership arrangement with Belfast Health and Social Care Trust (BHSCT). Complete financial backing is being furnished by Glaucoma UK alongside the HSC R&D Division.
The research design follows a pilot, randomized, cross-over methodology. Researchers will evaluate ART27.13’s ability to reduce intraocular pressure (IOP) among individuals diagnosed with glaucoma or ocular hypertension.
ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This classification indicates the compound activates cannabinoid receptors located in peripheral body tissues — including ocular structures — while avoiding central nervous system engagement.
Current glaucoma management options predominantly rely on topical eye drop formulations, which face challenges regarding patient compliance and sustained therapeutic benefit. According to Artelo, ART27.13’s molecular architecture may circumvent the psychoactive adverse effects that have historically hindered cannabinoid-based ocular therapies.
Regulatory clearance for the study protocol has been obtained from both an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Initial patient recruitment is projected for Q2 2026.
Professor Augusto Azuara-Blanco will serve as principal investigator. He holds the position of clinical professor of ophthalmology at Queen’s University Belfast and is internationally recognized for his glaucoma research contributions.
Glaucoma impacts over 80 million individuals globally and ranks among the primary causes of permanent vision loss. Raised IOP remains the principal modifiable risk factor driving disease advancement.
Artelo’s Capital-Efficient Strategy
CEO Greg Gorgas positioned the arrangement as a component of the company’s broader resource-conscious development approach. External funding sources will manage this investigation while Artelo maintains internal resource allocation toward ART27.13’s principal therapeutic target — cancer-associated anorexia.
“This collaboration exemplifies our capital-efficient development strategy,” Gorgas said in the announcement. “Each study contributes to a growing body of evidence that could enhance the value of ART27.13.”
Based on the collaboration terms, Artelo will provide ART27.13 capsules serving as the Investigational Medicinal Product throughout the trial. All additional financial obligations remain with the study’s external sponsors.
Recent Financial Context
The pre-market rally unfolds against a backdrop of financial headwinds. Artelo disclosed a net loss totaling $12.9 million for the fiscal year concluded December 31, 2025, representing an increase from the prior year’s $9.8 million deficit.
Cash reserves and investments registered at merely $0.6 million at that reporting date. InvestingPro’s Financial Health Score categorizes the organization as “WEAK.”
On March 10, 2026, the company executed a 1-for-3 reverse stock consolidation. Total outstanding common shares decreased from approximately 2.1 million to 708,323 shares following this capital restructuring.
Before Wednesday’s movement, ARTL had retreated 67% during the preceding six-month period. The security was exchanging hands at $4.85 with a market capitalization near $3.47 million ahead of the pre-market acceleration.
The glaucoma investigation marks Artelo’s inaugural venture into ophthalmological applications and its first externally-sponsored clinical collaboration.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
